U.S. Markets open in 7 hrs 22 mins

Abiomed Inc (ABMD) Files 10-K for the Fiscal Year Ended on March 31, 2019

- By insider

Abiomed Inc (ABMD) files its latest 10-K with SEC for the fiscal year ended on March 31, 2019. Abiomed Inc is a medical device company. It provides mechanical circulatory support devices to aid heart recovery to heart failure patients. Abiomed Inc has a market cap of $11.84 billion; its shares were traded at around $262.64 with a P/E ratio of 46.82 and P/S ratio of 16.47. Abiomed Inc had annual average EBITDA growth of 64.20% over the past five years.

For the last quarter Abiomed Inc reported a revenue of $207.1 million, compared with the revenue of $174.4 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $769.4 million, an increase of 29.6% from last year. For the last five years Abiomed Inc had an average revenue growth rate of 34.2% a year.

The reported diluted earnings per share was $5.61 for the year, an increase of 129% from previous year. Over the last five years Abiomed Inc had an EPS growth rate of 63.8% a year. The Abiomed Inc enjoyed an operating margin of 29.22%, compared with the operating margin of 26.47% a year before. The 10-year historical median operating margin of Abiomed Inc is 7.51%. The profitability rank of the company is 8 (out of 10).

At the end of the fiscal year, Abiomed Inc has the cash and cash equivalents of $121.0 million, compared with $43.0 million in the previous year. The company had no long term debt. Abiomed Inc has a financial strength rank of 10 (out of 10).

At the current stock price of $262.64, Abiomed Inc is traded at 142% premium to its historical median P/S valuation band of $108.53. The P/S ratio of the stock is 16.47, while the historical median P/S ratio is 6.80. The stock lost 31.29% during the past 12 months.

Directors and Officers Recent Trades:

  • Director Martin P Sutter sold 4,664 shares of ABMD stock on 05/08/2019 at the average price of $259.97. The price of the stock has increased by 1.03% since.

For the complete 20-year historical financial data of ABMD, click here.

This article first appeared on GuruFocus.